KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Other Operating Expenses (2019 - 2025)

Historic Other Operating Expenses for Novavax (NVAX) over the last 10 years, with Q3 2025 value amounting to $118.5 million.

  • Novavax's Other Operating Expenses rose 9553.94% to $118.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $184.6 million, marking a year-over-year decrease of 4248.71%. This contributed to the annual value of $51.9 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Novavax's Other Operating Expenses stood at $118.5 million, which was up 9553.94% from $15.3 million recorded in Q2 2025.
  • Novavax's 5-year Other Operating Expenses high stood at $434.6 million for Q3 2022, and its period low was $14.1 million during Q1 2025.
  • Its 4-year average for Other Operating Expenses is $106.5 million, with a median of $59.2 million in 2024.
  • Over the last 5 years, Novavax's Other Operating Expenses had its largest YoY gain of 12419.1% in 2023, and its largest YoY loss of 7942.39% in 2023.
  • Novavax's Other Operating Expenses (Quarter) stood at $181.8 million in 2022, then fell by 14.74% to $155.0 million in 2023, then crashed by 76.34% to $36.7 million in 2024, then skyrocketed by 223.25% to $118.5 million in 2025.
  • Its Other Operating Expenses was $118.5 million in Q3 2025, compared to $15.3 million in Q2 2025 and $14.1 million in Q1 2025.